Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare, Inc. reported proposed and recent sales of its common stock by a trust and an individual in a Form 144 disclosure. The filing lists multiple 10b5-1 plan sales including 180,000 shares on 03/10/2026, 180,000 on 02/10/2026, 180,000 on 01/12/2026, and a 605,648-share sale on 12/29/2025. It also shows 124,172 shares acquired from RSU vesting on 03/08/2022.
Alignment Healthcare, Inc. director and CEO John E. Kao reported an open-market sale of 180,000 shares of common stock at a weighted-average price of $18.1864 per share on March 10, 2026. The shares were held indirectly through the JEK Trust, where he serves as trustee. Following the sale, indirect holdings reported for the trust were 2,472,641 shares, and his direct holdings were 1,568,379 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 12, 2025.
JEK TRUST reported a proposed sale of 180,000 shares of Common Stock in a Form 144 filing. The filing lists an aggregate amount of $3,279,600.00 and references NASDAQ trading with a context figure of 204,296,493 shares and the date 03/10/2026.
The excerpt also shows prior 10b5-1 activity by the same trust: sales of 180,000 shares on 02/10/2026 and 01/12/2026 (amounts listed), and an earlier sale of 605,648 shares on 12/29/2025. The filing lists Morgan Stanley Smith Barney LLC in the securities section.
Alignment Healthcare, Inc. reported that Chief Human Resources Officer Andreas P. Wagner sold 21,118 shares of common stock in an open-market transaction on March 4, 2026 at a weighted-average price of $18.6216 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 21, 2025, with individual trade prices ranging from $18.47 to $18.89 per share. Following this transaction, Wagner directly owns 148,687 Alignment Healthcare shares.
ALHC affiliate filed a Form 144 to sell restricted stock units. The filing lists 21,118 restricted stock units associated with the issuer dated 03/13/2025. The filing also reports that Andreas Wagner sold 22,238 common shares on 02/10/2026 for $455,211.86.
Alignment Healthcare, Inc. disclosed that a selling stockholder entered into an underwriting agreement with J.P. Morgan Securities LLC for an underwritten public offering of 13,167,733 shares of its common stock. The sale closed on March 4, 2026, and the company will not receive any proceeds.
The transaction was conducted under an automatically effective Form S-3ASR shelf registration statement filed on March 2, 2026, using a base prospectus and a filed prospectus supplement. The agreement includes customary representations, covenants and indemnification, and the filing attaches the underwriting agreement and related legal opinion as exhibits.
Alignment Healthcare, Inc. registered 13,167,733 shares of its common stock for resale by a selling stockholder under a prospectus supplement dated March 2, 2026.
The prospectus supplement states we are not selling any shares under this supplement and will not receive any proceeds from the selling stockholder. The public offering price is $19.46 per share, with total public offering proceeds of $256,244,085 and underwriting discounts of $0.065 per share. Shares outstanding were 204,296,493 as of February 23, 2026.
Alignment Healthcare, Inc. files a shelf registration on Form S-3 to permit offers and sales of multiple securities. The registration statement establishes a shelf under which the company and named selling stockholders may offer debt securities, preferred stock, common stock, depositary shares, warrants, purchase contracts and units from time to time after the effective date.
The prospectus states that specific terms, amounts, prices and use of proceeds (issuer receipts for primary offerings; selling stockholders receive proceeds from resales) will be disclosed in subsequent prospectus supplements and that the securities may be offered in U.S. dollars or foreign currency.
Alignment Healthcare, Inc. presents its 2025 annual overview as a fast‑growing Medicare Advantage platform focused on senior care. Health Plan Membership reached 236,300 as of December 31, 2025, up from about 13,000 at inception, supported by AVA, its proprietary data and care-management technology.
The company reported a net loss of $1.0 million for 2025 versus $128.1 million in 2024, with an accumulated deficit of $1,009.0 million. Revenue and Health Plan Membership posted five‑year compound annual growth rates of 36% and 29%, respectively, and the business now spans 45 markets across five states.
Alignment highlights a highly regulated Medicare Advantage model, extensive use of in‑house clinical teams, and significant compliance obligations under CMS, HIPAA, state privacy laws and insurance regulations. It also discloses numerous risks, including sustained net losses, reimbursement dependence on CMS, cybersecurity threats, regulatory changes and intense industry competition.
Alignment Healthcare, Inc. reported strong fourth quarter and full-year 2025 results, beating the high end of its guidance across membership, revenue, adjusted gross profit and adjusted EBITDA. Full-year revenue reached $3.95 billion, up 46.1% year-over-year, with a medical benefits ratio of 87.5%.
Adjusted EBITDA for 2025 was $109.9 million, and income from operations turned positive at $14.8 million while net loss narrowed to $1.0 million. The company guided 2026 revenue to $5.14–$5.19 billion, implying about 30%–31% growth, and expects adjusted EBITDA of $133–$163 million. Year-end cash and cash equivalents were $575.8 million, supported by $139.9 million of operating cash flow in 2025.